Needham & Company Downgrades Neothetics Inc. (NEOT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Piper Jaffray Downgrades Neothetics Inc. (NEOT) to Neutral
December 15, 2015 6:45 AM ESTPiper Jaffray downgraded Neothetics Inc. (NASDAQ: NEOT) from Overweight to Neutral with a price target of $3.00 (from $20.00) after the company announced that lead product candidate LIPO-202 failed to meet its primary and secondary endpoints in pivotal studies evaluating the product for the localized reduction... More
Neothetics (NEOT) Reports LIPO-202 Phase 3s Missed co-Primary, Secondary Endpoints
December 14, 2015 4:31 PM ESTNeothetics, Inc. (NASDAQ: NEOT) announced top-line results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials to evaluate the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat. In both studies, LIPO-202 did not meet its co-primary composite and secondary endpoints. The co-primary endpoints were the proportion of subjects who reported an improvement of at least one point on the Patient-Global Abdominal Perception Scale (P-GAPS) and an improvement of at least two points on... More
